Bank of America
ALNY icon

Bank of America’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bank of America’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-700
Closed -$319K – 7328
2025
Q3 		$319K Buy
700
+300
+75% +$122K ﹤0.01% 6045
2025
Q2 		$130K Hold
400
– – ﹤0.01% 6383
2025
Q1 		$108K Buy
+400
New +$103K ﹤0.01% 6457
2024
Q4 		– Sell
-107,100
Closed -$29.5M – 8164
2024
Q3 		$29.5M Buy
107,100
+23,600
+28% +$6.14M ﹤0.01% 2035
2024
Q2 		$20.3M Buy
+83,500
New +$13.2M ﹤0.01% 2241
2023
Q4 		– Sell
-25,000
Closed -$4.43M – 7980
2023
Q3 		$4.43M Buy
+25,000
New +$4.77M ﹤0.01% 3517
2023
Q1 		– Sell
-2,700
Closed -$642K – 7774
2022
Q4 		$642K Sell
2,700
-146,800
-98% -$31.3M ﹤0.01% 5187
2022
Q3 		$29.9M Buy
149,500
+64,500
+76% +$12.3M ﹤0.01% 1642
2022
Q2 		$12.4M Buy
+85,000
New +$12.1M ﹤0.01% 2467
2020
Q1 		– Sell
-3,000
Closed -$346K – 6807
2019
Q4 		$346K Buy
+3,000
New +$299K ﹤0.01% 5269
2019
Q1 		– Sell
-9,300
Closed -$678K – 7075
2018
Q4 		$678K Buy
+9,300
New +$715K ﹤0.01% 4718
2018
Q2 		– Sell
-38,200
Closed -$4.55M – 7061
2018
Q1 		$4.55M Buy
38,200
+8,200
+27% +$1.06M ﹤0.01% 3169
2017
Q4 		$3.81M Sell
30,000
-33,000
-52% -$4.15M ﹤0.01% 3371
2017
Q3 		$7.4M Sell
63,000
-116,000
-65% -$9.9M ﹤0.01% 2810
2017
Q2 		$14.3M Buy
+179,000
New +$11.4M ﹤0.01% 2035
2015
Q3 		– Sell
-6,600
Closed -$791K – 7179
2015
Q2 		$791K Buy
+6,600
New +$789K ﹤0.01% 4311

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's ALNY Position: Q1 2026 in Review

Bank of America increased its Alnylam Pharmaceuticals (ALNY) stake by 41% in Q1 2026, buying an estimated $95.9M and bringing the position to 966,912 shares worth $320M. The position accounts for 0.02% of the portfolio, ranked #544.

Bank of America first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $683M in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Bank of America held 966,912 shares of Alnylam Pharmaceuticals worth $320M as of Q1 2026.
  • Bank of America bought 281,735 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $95.9M.
  • Alnylam Pharmaceuticals made up 0.02% of Bank of America's portfolio in Q1 2026, its #544 holding.
  • Bank of America first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Alnylam Pharmaceuticals position peaked at $683M in Q3 2025.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.